Good evening, you're tuned in to Markets Desk.
Fitch Ratings is sounding the alarm on Basel III reform, warning that proposed easing of U.S. bank capital rules could inflate reported capital ratios without actually strengthening balance sheets. The concern is that looser requirements would generate paper excess capital, potentially fueling buybacks at precisely the wrong moment in the credit cycle.
On the biotech tape, Wells Fargo has upgraded Editas Medicine to Overweight from Equal-Weight, a meaningful vote of confidence in the gene-editing firm. Editas trades on the Nasdaq and operates at the frontier of CRISPR-based therapeutics, a space where analyst conviction can move the needle sharply given the stock's sensitivity to institutional positioning.
And in fintech, stablecoin payments orchestration startup Anyflo has emerged from stealth, announcing simultaneously that it has acquired bitcoin lending platform Native. The move signals a push to consolidate crypto-native financial infrastructure under one roof, targeting enterprise clients who want stablecoin payment flows without building the plumbing themselves.
That's the tape. Markets Desk, signing off the floor.
